Security key
61023L207
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 6,646,654
- Total 13F shares
- 2,886,019
- Share change
- +307,724
- Total reported value
- $109,374,138
- Price per share
- $36.41
- Number of holders
- 34
- Value change
- +$11,536,779
- Number of buys
- 23
- Number of sells
- 6
Report period
Q1 2025
Institutions
34
Top holders
10
MNPR full security history
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Monopar Therapeutics SEC filings
Monopar Therapeutics company facts
Monopar Therapeutics 13D/G history
Broader feeds
Reporting periods
Holder history for CUSIP 61023L207
Recent filing periods:
Top shareholders of MNPR - Monopar Therapeutics - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
16%
|
1,046,899
|
$23,434,834 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
9%
|
599,195
|
$13,182,290 | — | 31 Dec 2024 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
7.7%
|
511,207
|
$11,246,554 | — | 31 Dec 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.5%
|
167,892
|
$3,693,624 | — | 31 Dec 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
2%
|
130,037
|
$2,860,814 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.85%
|
56,509
|
$1,243,198 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.58%
|
38,596
|
$849,112 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.12%
|
8,101
|
$178,222 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
6,423
|
$141,306 | — | 31 Dec 2024 | |
| Michael J. Brown |
3/4/5
|
Director |
—
class O/S missing
|
402,530
|
$136,941 | — | 31 Dec 2023 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.09%
|
5,908
|
$129,976 | — | 31 Dec 2024 | |
| Andrew Paul Mazar |
3/4/5
|
Chief Scientific Officer, Director |
—
mixed-class rows
|
277,584
mixed-class rows
|
$94,434 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.06%
|
3,801
|
$83,622 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.03%
|
2,037
|
$44,814 | — | 31 Dec 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
696
|
$15,312 | — | 31 Dec 2024 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0.01%
|
600
|
$13,200 | — | 31 Dec 2024 | |
| Karthik Radhakrishnan |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
126,550
mixed-class rows
|
$10,447 | — | 28 Oct 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
250
|
$5,500 | — | 31 Dec 2024 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
100
|
$2,200 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
28
|
$616 | — | 31 Dec 2024 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
16
|
$352 | — | 31 Dec 2024 | |
| Jose Octavio Pinto Costa Filho |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
91,500
|
— | — | 12 Jul 2021 |
Institutional Holders of Monopar Therapeutics - Common Stock (MNPR) as of Q1 2025
As of 31 Mar 2025,
Monopar Therapeutics - Common Stock (MNPR) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,886,019 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, ADAGE CAPITAL PARTNERS GP, L.L.C., RA CAPITAL MANAGEMENT, L.P., Point72 Asset Management, L.P., ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, and MARSHALL WACE, LLP.
This page lists
35
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
18
Q1 2025 holders
34
Holder diff
16
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.